VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SUPN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SUPNSupernus Pharmaceuticals, Inc.
$29.04$3.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSUPNBalance Sheet

Supernus Pharmaceuticals, Inc. (SUPN) Balance Sheet

18Y historyFree accessUpdated daily

Total debt jumped from $40.2M to $501.0M in a single quarter while equity turned negative at -$60.0M, leaving debt-to-equity not meaningful and the current ratio compressed to 0.61 from 2.08 despite $305.0M in cash.

Income StatementBalance SheetCash FlowRatios

SUPN Balance Sheet

Annual statement

SUPN Balance Sheet

Supernus Pharmaceuticals, Inc. (SUPN) balance sheet — 18-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Total Current Assets800M652M839M1.27B1.27B1.44B1.19B1.36B1.33B1.22B990M105.98M108.89M97.16M91.74M49.4M39.81M72.88M69.46M
Cash & Short-Term Investments305M195M320M410M897.83M1.1B858M1.06B924M863M692M62.19M74.34M82.19M88.51M48.54M32.7M66.52M60.38M
Cash Only305M195M319M316M778.18M1.1B858M1.06B924M863M692M62.19M74.34M82.19M88.51M48.54M23.74M31.41M52.88M
Short-Term Investments001M94M119.64M000000000008.96M35.12M7.5M
Accounts Receivable286M255M254M254M220M202M219M204M278M257M205M25.91M17.27M5.05M675K0158K3.74M2.28M
Days Sales Outstanding73.9275.1278.0484.8289.1293.21123.5594.85105.7181.777.2365.4851.65153.48166.47-544.0636.0193.47
Inventory149M153M178M135M114.62M95M93M73M78M52M41M12.59M13.44M7.15M1.15M389K6.75M2.35M6.55M
Days Inventory Outstanding270.17227.01281.26283.19277.05273.03349.95190.32211.4154.44135.05545.44852.032.36K---183.94-99.751000K
Other Current Assets39M15M34M444M18M27M0049M38M40M03.85M0144K06.75M00
Total Non-Current Assets532M552M481M499M512.76M388M344M292M218M219M219M82.75M28.62M13.83M2.25M4.33M7.2M7.02M7.68M
Property, Plant & Equipment187M170M139M124M85.46M95M103M107M57M54M27M3.87M2.45M2.55M1.42M1.31M1.25M1.86M1.99M
Fixed Asset Turnover7.64x7.29x8.55x8.81x10.54x8.33x6.28x7.34x16.84x21.26x35.88x37.28x49.85x4.71x1.04x0.61x0.08x20.40x4.47x
Goodwill002M0000000000000000
Intangible Assets2M2M5M13M70M82M62M72M000976K5.43M1.16M683K912K1.14M1.37M1.6M
Long-Term Investments109M28M26M41M98.53M00033M15M055.01M19.82M8.76M00000
Other Non-Current Assets28M26M29M28M38.58M106M104M73M84M92M83M391K6.35M1.52M144K2.11M4.8M3.79M4.09M
Total Assets1.33B1.2B1.32B1.76B1.78B1.83B1.53B1.65B1.55B1.44B1.21B188.73M137.51M111M93.99M53.73M47.01M79.9M77.13M
Asset Turnover1.11x1.03x0.90x0.62x0.51x0.43x0.42x0.48x0.62x0.80x0.80x0.77x0.89x0.11x0.02x0.01x0.00x0.47x0.12x
Asset Growth %-42.68%-8.72%-25.27%-0.76%-2.92%19.66%-7.32%6.79%7.13%19.44%540.6%37.25%23.89%18.09%74.93%14.3%-41.16%3.58%-
Total Current Liabilities1.3B914M939M1.29B1.02B804M599M742M818M854M1.03B56.1M27.49M26.4M22.98M18.77M15.21M10.03M8.27M
Accounts Payable28M48M63M39M33M26M416M499M47M40M33M4.31M1.86M3.14M2.81M10.08M11.26M6.25M4.47M
Days Payables Outstanding63.0771.2299.5581.8179.7774.721.57K1.3K127.38118.8108.7186.94118.11.04K---306.7-265.421000K
Short-Term Debt488M39M18M12M3M3M12M9M4M5M101M497K0011.81M6.78M000
Deferred Revenue (Current)00009.05M00024M41M52M176K143K8.09M508K232K000
Other Current Liabilities77M722M802M1.16B391M635M156M195M603M617M673M26.79M19.7M10.16M7.86M1.55M2.5M1.29M2.5M
Current Ratio0.61x0.71x0.89x0.98x1.24x1.80x1.98x1.83x1.62x1.43x0.96x1.89x3.96x3.68x3.99x2.63x2.62x7.26x8.39x
Quick Ratio0.50x0.55x0.70x0.88x1.12x1.68x1.83x1.73x1.53x1.37x0.92x1.66x3.47x3.41x3.94x2.61x2.17x7.03x7.60x
Cash Conversion Cycle281.02230.91259.75286.2286.41291.52-1.09K-1.02K189.72117.34103.58423.98785.581.48K--666.81201.681000K
Total Non-Current Liabilities91M388M728M666M702.78M825M850M701M663M793M474M13.76M38.66M51.13M13.44M25.52M76.12M76.02M75.61M
Long-Term Debt0290M315M237M237M239M230M233M237M477M434M7.08M26.95M34.39M11.09M22.71M75M75M75M
Capital Lease Obligations55M22M32M34M29M36M43M51M0000000-942K000
Deferred Tax Liabilities3M3M05M0000000854K6.56M12.64M-309K942K00-75M
Other Non-Current Liabilities85M73M381M390M436.78M550M577M417M426M316M40M35.21M10.44M15.32M2.04M1.4M1.12M1.02M169.62K
Total Liabilities1.39B1.3B1.67B1.96B1.73B1.63B1.45B1.44B1.48B1.65B1.5B69.86M66.15M77.53M36.42M44.29M91.33M86.06M83.88M
Total Debt501M351M375M283M277M286M285M293M241M482M535M7.19M26.95M34.39M22.9M29.49M75M75M75M
Net Debt196M156M56M-33M-501.18M-816M-573M-767M-683M-381M-157M-55M-47.39M-47.8M-65.61M-19.06M51.26M43.59M22.12M
Debt / Equity-8.35x---5.40x1.41x3.48x1.40x3.65x--0.06x0.38x1.03x0.40x3.12x---
Debt / EBITDA0.82x1.23x6.25x--1.22x-1.42x0.72x1.10x1.52x0.39x1.07x----14.74x-
Net Debt / EBITDA0.32x0.55x0.93x---3.47x--3.72x-2.05x-0.87x-0.45x-2.96x-1.88x----8.57x-
Interest Coverage32.65x6.31x1.34x-3.26x-2.14x8.31x-6.21x9.18x9.52x3.94x2.68x4.37x4.42x-10.76x-11.95x-20.15x---2.86x
Total Equity-60M-98M-348M-191M51.28M203M82M209M66M-203M-295M118.88M71.35M33.46M57.57M9.44M-44.32M-6.16M-6.75M
Equity Growth %211.88%71.84%-82.2%-472.5%-74.74%147.56%-60.77%216.67%132.51%31.19%-348.16%66.6%113.23%-41.87%509.66%121.31%-619.95%8.76%-
Book Value per Share-0.49-0.77-2.62-1.350.371.320.561.380.44-1.36-1.982.321.411.053.300.68-3.20-0.44-0.49
Total Shareholders' Equity-60M-98M-348M-191M51.28M203M82M209M66M-203M-295M118.88M71.35M33.46M57.57M9.44M-44.32M-6.16M-6.75M
Common Stock062M62M68M68.37M70M73M73M73M72M72M49K43K40K31K14K2K6K5.52K
Retained Earnings-197M-243M-454M-295M1.31B1.44B1.31B1.45B1.31B1.03B950M-144.64M-158.66M-178.53M-86.25M-39.97M-93.79M-55.32M-55.78M
Treasury Stock0000000000000000000
Accumulated OCI-26M-30M-46M-1.35B-1.34B0-1.31B-1.32B-1.33B-1.31B-1.32B-488K-154K0-57K1K02K-2.15M
Minority Interest0000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Negative equity after acquisition outflow

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Swings Negative After Acquisition Spending

According to the supplied balance sheet, SUPN's equity fell from roughly $1.0B in 2026Q2 to -$60.0M in 2026Q3 while total liabilities rose to $1.4B, a shift that appears driven by the large acquisition-related outflow and debt build.

The reported figures suggest the balance sheet weakened sharply in the latest quarter rather than gradually, with total debt climbing from $40.2M to $501.0M alongside a drop in retained earnings from $457.2M to -$197.0M. This pattern indicates the recent acquisition was funded largely with borrowing and reserves, which may limit financial flexibility until the acquired assets are shown to generate durable earnings. Investors should monitor whether the negative equity position persists and how quickly the debt load is serviced.

Leverage Jumps From Minimal to Material

Based on reported figures, SUPN's total debt rose from $40.2M to $501.0M in one quarter, lifting debt-to-equity from 0.04 to a negative ratio that is not meaningful under negative book equity.

Prior to 2026Q3 the company carried very low leverage, so the jump appears strategic in nature, tied to the acquisition rather than operating needs. The negative equity makes conventional leverage ratios unreliable, so the more relevant measure is debt relative to cash of $305.0M, which suggests net debt of roughly $196M. Refinancing terms and the timing of repayment warrant further investigation, as the reported data does not disclose maturity schedules.

Goodwill Largely Absent Despite Acquisition

As reported in the balance sheet, SUPN's goodwill was $119.4M in 2026Q2 but only $2.0M in 2026Q3, while total assets remained near $1.3B to $1.4B, which raises questions about how acquired value was classified.

The sharp decline in goodwill alongside a large asset base suggests the acquisition may have been recorded primarily as identifiable intangibles or other assets rather than goodwill, though the supplied data does not confirm this allocation. The PPE base of $187.0M in the latest quarter versus $35.6M prior also points to a material asset addition that may warrant closer review. The asset mix shift implies a more asset-heavy profile than the company historically carried.

Current Ratio Compresses With Rising Obligations

According to the reported figures, SUPN's current ratio declined from 2.08 in 2026Q2 to 0.61 in 2026Q3, while cash of $305.0M provides a partial buffer against the increase in current obligations.

A current ratio below 1.0 indicates current liabilities now exceed current assets, a meaningful change from the prior comfortable level near 2.0. Cash has also risen from $180.0M to $305.0M, which appears to offset some of this pressure, but the reported data does not break out the maturity profile of liabilities. Liquidity should be assessed in conjunction with cash flow durability, which has been volatile across recent quarters.

Negative Equity Masks Underlying Cash Position

The most misleading headline is the negative book equity of -$60.0M, which may overstate balance sheet distress given $305.0M in cash, yet it may also signal that prior accumulated earnings were largely consumed by the acquisition.

Because retained earnings swung from $457.2M to -$197.0M in one quarter, the equity figure appears driven by a large charge or distribution rather than ongoing operating losses, a distinction the supplied data alone cannot confirm. Headline leverage and equity metrics therefore may not reflect the company's true capacity to service debt. Investors should monitor whether future cash flow, rather than book equity, supports the balance sheet going forward.

SUPN — Frequently Asked Questions

Quick answers to the most common questions about buying SUPN stock.

What are the total assets of Supernus Pharmaceuticals, Inc. (SUPN)?

As of 2025, Supernus Pharmaceuticals, Inc. (SUPN) had total assets of $1.20B including $652.0M in current assets.

How much debt does Supernus Pharmaceuticals, Inc. (SUPN) have?

Supernus Pharmaceuticals, Inc. (SUPN) carries total debt of $351.0M, offset by $195.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Supernus Pharmaceuticals, Inc.?

Supernus Pharmaceuticals, Inc. (SUPN) has total shareholders' equity (book value) of $-98.0M ($-0.77 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Supernus Pharmaceuticals, Inc.'s current ratio and liquidity?

Supernus Pharmaceuticals, Inc. (SUPN) reported a current ratio of 0.71x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.